Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA-HFpEF: BMS-986435 in Heart Failure With Preserved Ejection Fraction
NCT06122779Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of BMS-986435 in heart failure with preserved ejection fraction (HFpEF), sponsored by Bristol Myers Squibb. Started Nov 2023; status: active, not recruiting.
02
Drugs
BMS-986435
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06122779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122779.